- GeoVax Highlights Strategic Alignment of GEO-MVA with HHS/ASPR’s Five-Year Medical Countermeasure Preparedness Strategy
- GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness
- GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers
- GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses
- GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
- GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness
- Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event
- GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)
- GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
- GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats
- GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules
- GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans
- GeoVax Highlights Emerging Role of Gedeptin® in Combination Immunotherapy Strategies Targeting Immunologically “Cold” Tumors
- GeoVax Announces a Warrant Inducement Transaction
- GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
- GeoVax Advances Gedeptin® Toward Phase 2 Initiation and Strategic Partnership Opportunities
- GeoVax Highlights Gedeptin® as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies
- GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
- GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market
- GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026
- GeoVax Announces a Warrant Inducement Transaction
- GeoVax Provides Update on GEO-MVA Program
- GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients
- GeoVax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox/Smallpox Vaccine
- GeoVax Announces Oncology Advisory Board to Advance Gedeptin® Development Across Solid Tumors
- GeoVax Secures Exclusive License for Gedeptin® + Immune Checkpoint Inhibitor Combination Technology
- GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far from Over
- GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- GeoVax Highlights 2026 as a Pivotal Year for Progress
- GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
- GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week
- GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering
- GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA
- GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 Vaccine
- GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026
- GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design
- GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients
- GeoVax Addresses Identification of New Mpox Variant
- GeoVax Announces Addition of Renowned Global Experts to its Scientific Advisory Board
- GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin® Gene Therapy
- GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin® in Recurrent Head & Neck Cancer
- GeoVax to Present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference
- GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update
- GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in Vaccination
- GeoVax to Report Third Quarter 2025 Financial Results and Provide Corporate Update on November 13, 2025
- GeoVax Announces Relocation of Corporate Headquarters and Laboratory Operations to Support Accelerated Growth and Pipeline Advancement
- BIO CEO Warns U.S. Could Lose Biotech Leadership Within Two Years; GeoVax Calls on Congress and Administration to Act Now
- GeoVax Connects IDSA Guidance on COVID-19 Vaccination for Immunocompromised Patients with Recent Clinical Data for GEO-CM04S1
- GeoVax Welcomes New IDSA Guidance Highlighting Need for Tailored COVID-19 Vaccines for Immunocompromised Patients
- GeoVax Highlights Urgent Need for Multisource Mpox Vaccine Supply Following California Clade 1 Cases
